Check our new paper Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

First $ARVN, then $KYMR, now $NRIX PROTACS work!!! Not sure this class gets the credit it deserves for its huge potential. Still early days and chemistry isn't trivial but the potential here is huge: The ability to degrade every protein with an oral small molecule...

Happy to announce our new work identifying cdk6 in lenalidomide resistant multiple myeloma published in Nature Communications rdcu.be/cHA4R great collaboration Charité - Universitätsmedizin Berlin Max Delbrück Center

Our AML-Team has published their "Mito-AML" story Cancer Cell. 👏🎉Congrats to all authors! The proteogenomic subtypes of acute myeloid leukemia sciencedirect.com/science/articl… VomLaborInDiePraxis Goethe-Universität Matthias Mann Lab

Glad to see our work on #SARSCoV2 inhibiting semisynthetic compounds on the front cover of ChemMedChem !!! Thanks 🙏 to collaborators UFZ agmueller.unibonn Rheinische Friedrich-Wilhelms-Universität Bonn Izidor Sosič Uniklinik Bonn #chemtwitter Article is #OpenAccess (DEAL). Link to our work 👉 tinyurl.com/4s8k9fzk

Very excited to share our latest work, now published online first in Cancer Discovery! Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts aacrjournals.org/cancerdiscover…

Our latest TPD research now online as a preprint: Expanding the PROTAC Toolbox: Targeted Degradation of the Deubiquitinase USP7 in Cancer | ChemRxiv. lmy.de/VQrs8 #chemtwitter Krönke Lab Izidor Sosič

We employed the BTB domain of transcription factor BCL6 as small-molecule-controlled reversible oligomerization switch. Led by Lena and my first corresponding author manuscript Cell Reports Methods 1/16 cell.com/cell-reports-m…

It's the E3 ligase Smac-down!🥊VHL and CRBN face IAPs head to head.🥊Who shall prevail? Welp, our preprint title gives it out, IAPs get totally K.O.'d. bit.ly/3QHGGEV. A great collaboration from Christian Steinebach, Krönke Lab, Alesa Bricelj and Izidor Sosič #TPD #PROTACs

Excited to announce that our lab has been awarded an #ERC_StG grant to study immunological interactions in leukemias. Thanks to our team members, collaborators, friends and family for the constant support! @berlinnovation Max Delbrück Center Charité - Universitätsmedizin Berlin European Research Council (ERC)

Our paper on using heteroPROTACs to induce potent pan-IAP degradation is finally out! Check out our results from the IAP vs VHL&CRBN battle 🥊—> bit.ly/3K0aMCp Very happy about this great collaboration with our established team 😁Izidor Sosič Christian Steinebach, Krönke Lab

We had a record number of (high quality) abstracts for this year’s Mol Hem workshop European Hematology Association annual meeting. Check out the 12 selected talks ehaweb.org/congress/eha20…

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus | New England Journal of Medicine nejm.org/doi/full/10.10…

Early View | Haematologica haematologica.org/article/view/h… Finally first results from our Phase 1 TCR study targeting MAGE-A1 in myeloma! Hopefully more to come in advanced solid tumors where need for innovative (cellular) therapies is still HUGE.

Protein-Genomics Myeloma Session #ASH24 chaired by Dr Paola Neri ⁦Francesco Maura⁩ @kronkelab ⁦Fabiana Perna⁩